2016 Hematological Malignancies

Relapsed and refractory Lymphoma Summary

• Prognosis of r&r HL still to be improved • DHAP or other reinduction followed by BEAM and ASCT standard in relapsed lymphoma; intensification not helpful (HDR2) • BV effective and well tolerated; currently being evaluated in combination with other drugs • Anti-PD1 ´ s represent a new class of drugs showing very promising activity in r/r lymphoma • GHSG to conduct trials with anti-PD1 ´ s in cHL (early favorable, unfavorable, abscopal) • Can new drugs replace radio- or chemotherapy in lymphoma?